AXSM vs MDGL
Axsome Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc., both Healthcare
Axsome Therapeutics, Inc. is the larger company at $12B against $12B. Over the past year AXSM returned +45% against +7.3% for MDGL. The RyuScore puts AXSM ahead, 18 against 11 out of 100.
| Figure | AXSM | MDGL |
|---|---|---|
| Last close | $168 | $472 |
| Market cap | $12B | $12B |
| 1-year return | +45% | +7.3% |
| 5-year return | +544% | +496% |
| RyuScoresector-relative, 1–10 | 18/100 | 11/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Axsome Therapeutics, Inc.
Revenue of $218M in Q2 2026, net income null. Its largest reported line is Royalty And Milestone, 66% of the disclosed total.
Madrigal Pharmaceuticals, Inc.
Revenue of $364M in Q2 2026, net income null.
Open these two in the interactive comparison to add more names, change the period or see the correlation.